Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

244.67 -3.71 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
From Insulet Corporation
Via Business Wire
Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
From Insulet Corporation
Via Business Wire
Insulet to Present at Nasdaq’s 45th Investor Conference
From Insulet Corporation
Via Business Wire
10 Biggest Price Target Changes For Monday
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wedbush raised Uber Technologies, Inc. (NYSE:UBER)... 
Via Benzinga
Insulet Corporation (PODD) Q3 2021 Earnings Call Transcript
PODD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Insulet Posts Mixed Third Quarter, But Raises Sales Guide On Narrow Beat
Insulet raised its full-year sales outlook Thursday on its third-quarter sales beat. 
Via Investor's Business Daily
Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Insulet Honors Diabetes Awareness with Global Activities and Events
From Insulet Corporation
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford
From Insulet Corporation
Via Business Wire
Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System. Omnipod 5 is a... 
Via Benzinga
Insulet’s Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
From Insulet Corporation
Via Business Wire
Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021
From Insulet Corporation
Via Business Wire
5 Top Stocks for September
Our analysts give you five picks you can add to your portfolio today. 
Via The Motley Fool
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Looking into Insulet's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Insulet (NASDAQ:PODD) earned $26.30 million, a 61.35% increase from the preceding quarter. Insulet also posted a... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
The 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States
From Insulet Corporation
Via Business Wire
Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress
From Insulet Corporation
Via Business Wire
Insulet Stock Dives On Unexpected Delay For Next-Generation Insulin Pump
Insulet said Thursday it expects a one-quarter delay for its next-generation insulin pump, leading PODD stock to tumble on Friday. 
Via Investor's Business Daily
Insulet Corporation (PODD) Q2 2021 Earnings Call Transcript
PODD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year
From Insulet Corporation
Via Business Wire
3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain
Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021
From Insulet Corporation
Via Business Wire
Insulet’s Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 years
From Insulet Corporation
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.